Multi-site research collaborations often treat a shared protocol as the single source of truth. A peptide name, catalogue code or batch reference may appear on that protocol because a laboratory has designed an in-vitro assay, a materials manager has sourced a research-use-only item, or a partner site has asked for a comparable reagent. None of those entries, on their own, grants permission for human or veterinary use. The name is an identifier for a research material; it is not a regulatory classification, a clinical authorisation, a dosing instruction or a licence to administer anything to a person or an animal. That distinction becomes harder to police as documents move between sites, because a line copied from one protocol can acquire false authority in another institution’s folder.
The Protocol Label Is a Research Question, Not a Regulatory Clearance
A protocol may list BPC-157 10mg, TB-500 5mg or GHK-Cu 50mg as research materials alongside assay buffers and controls. At one site, that entry may support a cell-signalling study; at another, it may be copied into a different experimental design without the same ethics review, waste route or laboratory risk assessment. The material remains research-use-only throughout. A peptide name does not convert a research reagent into a medicine, medical device, injectable, treatment or food supplement under UK law. Research Sciences supplies high-purity research peptides, laboratory accessories and preparation tools for controlled in-vitro scientific research, and its stated position is that products are not supplied for therapeutic, clinical or diagnostic purposes. The purchaser remains responsible for lawful use, safe handling, storage, disposal and compliance with COSHH and laboratory safety standards.
The same caution applies to reconstitution language. In an in-vitro workflow, a researcher may calculate diluent volume and working concentration for an assay, using the shop’s free reconstitution calculator only as a laboratory aid. That calculation does not authorise administration to humans or animals, and the shop’s materials and calculator are not for medical or clinical use. A multi-site team should therefore record the research question, model system, controls, solvent compatibility and waste route next to the catalogue line. A project team may locate a listing through the Peptide uk catalogue and then treat the name on a protocol as if it were transferable authority; it is not. The protocol must show that each site has checked suitability for its own lawful research application, not merely that the same peptide name appears in a shared document. Products are labelled “For Research Use Only – Not for Human Consumption”, and the shop describes this as in line with MHRA guidance; this is the shop’s stated position, not legal advice.
Documentation, Batch Traceability and the Limits of a Shared File
A shared file can travel faster than a batch record. Research Sciences publishes that compounds are independently tested and that CoAs accompany products; the homepage lists “CoAs Janoshik Analytical Reports”, and the FAQs state that exact purity is stated on the CoA. Those are published claims to verify against the specific batch document, not a substitute for site-level review. A label reference such as BPC10-03/27 combines SKU and expiry and links to the corresponding CoA; quote that reference when contacting the shop about documentation. The practical question for a materials manager is not whether the peptide name looks familiar, but whether the exact vial, batch and CoA can be matched to the approved research use at each site.
Multi-site collaborations need a central register that records catalogue item, batch label, CoA version, storage condition, dispatch tracking and site acceptance checks. An Internal Test Reference may be reused on restocked products and links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or have had separate independent testing. Vial cap colour and packaging can vary and are not indicators of identity, analytical quality or manufacturing origin. The register should distinguish between a product-page claim, the batch CoA and a local protocol appendix. It should also record that materials are not for human or veterinary use and that no site may convert a research reagent into a therapeutic, clinical or diagnostic product. Orders are described as dispatched the next working day, with Royal Mail Tracked 24 usually delivering the following working day as an estimate; tracking is provided after dispatch, and delivery times can vary. No returns are accepted once dispatched, and refunds are limited to damage, incorrect supply or quality issues under the published policy. Older pages may use Imperial Sciences UK or Imperial Peptides UK; the FAQs describe Research Sciences as the parent company of Imperial Peptides UK, which continues to operate as a brand.
Governance Boundaries for Collaboration Sites
A collaboration agreement should name the permitted research use clearly: controlled laboratory and analytical work, with no human or veterinary use, no clinical or diagnostic application and no administration to persons or animals. It should also assign responsibility for COSHH assessment, waste disposal and local approvals at each site. The shop does not provide therapeutic, medical, performance, injection, ingestion or dosing guidance, and orders inconsistent with its compliance standards may be refused. Those boundaries should be repeated in site inductions, not buried in a shared protocol appendix. A peptide name on a protocol is not a licence for a partner laboratory to change the use case, share material outside the approved research team or treat a research-use-only item as though it were a medicine.
Storage and handling terms belong inside the same governance framework. The shop’s research-use guidance is to allow vials to reach room temperature before opening, work in a clean environment, remove only the amount required for the experiment, and store lyophilised peptides at –20°C or below, sealed with desiccant and protected from moisture, heat and light. Repeated freeze–thaw cycles should be avoided. Reconstituted peptides are less stable and should be kept at 2–8°C for short-term laboratory use. These instructions support in-vitro workflow only; they are not preparation advice for human or veterinary use. Materials managers should mirror those conditions in site storage logs and dispatch checks, and researchers should confirm that the batch CoA and label reference match the material received. Temperature-aware storage and tracked UK dispatch are published service features, but each site still needs its own receipt check and deviation record. The same rule applies to the free reconstitution calculator: it is a laboratory aid for assay concentration, not a medical or clinical tool.
For multi-site work, the safest control is to separate the peptide name from the permission to use it. A protocol can identify a catalogue item such as Tesamorelin 5mg or Ipamorelin 5mg as a research material, but the permission to proceed must come from the site’s own approved protocol, risk assessment and lawful research purpose. Materials remain research-use-only and not for human or veterinary use at every stage, including after dispatch, storage, reconstitution and analytical use. If a site cannot connect the exact batch, CoA and approved in-vitro application, the name in the shared file is merely a label, not a licence.
